Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16945481rdf:typepubmed:Citationlld:pubmed
pubmed-article:16945481lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16945481lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:16945481lifeskim:mentionsumls-concept:C0079731lld:lifeskim
pubmed-article:16945481lifeskim:mentionsumls-concept:C0005516lld:lifeskim
pubmed-article:16945481lifeskim:mentionsumls-concept:C0071744lld:lifeskim
pubmed-article:16945481lifeskim:mentionsumls-concept:C0035020lld:lifeskim
pubmed-article:16945481pubmed:issue2lld:pubmed
pubmed-article:16945481pubmed:dateCreated2007-3-6lld:pubmed
pubmed-article:16945481pubmed:abstractTextThe concentration of cysteine protease inhibitor cystatin C was determined in sera from 59 patients with non-Hodgkin B-cell lymphoma using ELISA. The sera from 43 age and sex matched healthy blood donors served as controls. Cystatin C was significantly increased in sera of patients without therapy (mean 1136+/-SE 105.7ng/ml, p=0.00001) and with therapy (mean 1073+/-52ng/ml, p=0.001) compared to controls (mean 819+/-28ng/ml). The highest levels were determined in sera of patients with a relapse (mean 1680+/-196ng/ml). By using immunofluorescence staining and confocal microscopy we determined immature dendritic cells as a major population of cystatin C positive cells in affected lymph nodes. Our study reports for the first time that cystatin C is a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma.lld:pubmed
pubmed-article:16945481pubmed:languageenglld:pubmed
pubmed-article:16945481pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16945481pubmed:citationSubsetIMlld:pubmed
pubmed-article:16945481pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16945481pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16945481pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16945481pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16945481pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16945481pubmed:statusMEDLINElld:pubmed
pubmed-article:16945481pubmed:monthAprlld:pubmed
pubmed-article:16945481pubmed:issn0304-3835lld:pubmed
pubmed-article:16945481pubmed:authorpubmed-author:KosJankoJlld:pubmed
pubmed-article:16945481pubmed:authorpubmed-author:Begi?LejlaLlld:pubmed
pubmed-article:16945481pubmed:authorpubmed-author:Mulaomerovi?A...lld:pubmed
pubmed-article:16945481pubmed:authorpubmed-author:Cickusi?Elmir...lld:pubmed
pubmed-article:16945481pubmed:authorpubmed-author:Halilbasi?Alm...lld:pubmed
pubmed-article:16945481pubmed:authorpubmed-author:Zavasnik-Berg...lld:pubmed
pubmed-article:16945481pubmed:issnTypePrintlld:pubmed
pubmed-article:16945481pubmed:day18lld:pubmed
pubmed-article:16945481pubmed:volume248lld:pubmed
pubmed-article:16945481pubmed:ownerNLMlld:pubmed
pubmed-article:16945481pubmed:authorsCompleteYlld:pubmed
pubmed-article:16945481pubmed:pagination192-7lld:pubmed
pubmed-article:16945481pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:meshHeadingpubmed-meshheading:16945481...lld:pubmed
pubmed-article:16945481pubmed:year2007lld:pubmed
pubmed-article:16945481pubmed:articleTitleCystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma.lld:pubmed
pubmed-article:16945481pubmed:affiliationMedical Faculty, University of Tuzla, Bosnia and Herzegovina.lld:pubmed
pubmed-article:16945481pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16945481pubmed:publicationTypeHistorical Articlelld:pubmed
pubmed-article:16945481pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16945481lld:pubmed